Loading...
Loading...
Also known as: Nicotinamide Mononucleotide, β-NMN
A direct NAD+ precursor that restores declining cellular energy metabolism and activates sirtuins for anti-aging effects.
Nicotinamide Mononucleotide (NMN) is a nucleotide derived from ribose and nicotinamide that serves as a direct biosynthetic precursor to NAD+ (nicotinamide adenine dinucleotide). NAD+ levels decline ~50% between ages 40-60, contributing to metabolic dysfunction and aging.
Both NMN and NR (nicotinamide riboside) are NAD+ precursors. NMN is one step closer to NAD+ in the biosynthetic pathway, and recent research identified a dedicated NMN transporter (Slc12a8) enabling direct cellular uptake.
NMN is converted to NAD+ via nicotinamide mononucleotide adenylyltransferase (NMNAT) enzymes. Elevated NAD+ activates sirtuins (SIRT1-7), PARPs (DNA repair), and CD38, supporting mitochondrial function, DNA maintenance, and metabolic regulation.
Typical Dose
250-1000mg
Frequency
Daily (morning)
Cycle Length
Ongoing
Half-Life
~2-3 hours (but NAD+ elevation lasts longer)
Multiple human clinical trials completed and ongoing. Generally recognized as safe supplement.
Well-tolerated in human trials at doses up to 1200mg/day. No significant adverse effects reported. Long-term safety data still accumulating. Theoretical concern about fueling cancer cell metabolism — though not demonstrated in clinical studies.
An mTOR inhibitor and FDA-approved immunosuppressant being investigated as the most promising pharmacological intervention for extending lifespan.
The world's most prescribed diabetes drug, now being studied as a potential anti-aging intervention in the landmark TAME clinical trial.
A polyphenol found in red wine and grapes that activates sirtuins and AMPK, studied extensively for its anti-aging and cardioprotective properties.